273 related articles for article (PubMed ID: 27274393)
1. Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma.
Vo KT; Matthay KK; DuBois SG
Clin Sarcoma Res; 2016; 6():9. PubMed ID: 27274393
[TBL] [Abstract][Full Text] [Related]
2. Recent concepts of antiangiogenic therapy.
Konno H; Yamamoto M; Ohta M
Surg Today; 2010 Jun; 40(6):494-500. PubMed ID: 20496129
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and antiangiogenic approaches to sarcomas.
Heymach JV
Curr Opin Oncol; 2001 Jul; 13(4):261-9. PubMed ID: 11429484
[TBL] [Abstract][Full Text] [Related]
4. Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor.
Martin-Broto J; Hindi N
Curr Opin Oncol; 2016 Jul; 28(4):338-44. PubMed ID: 27166665
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
6. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies in sarcomas: challenging the challenge.
Martín Liberal J; Lagares-Tena L; Sáinz-Jaspeado M; Mateo-Lozano S; García Del Muro X; Tirado OM
Sarcoma; 2012; 2012():626094. PubMed ID: 22701332
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas?
Martin-Liberal J; Tirado OM; García del Muro X
Expert Rev Anticancer Ther; 2015 Mar; 15(3):257-9. PubMed ID: 25586480
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.
D'Adamo DR; Dickson MA; Keohan ML; Carvajal RD; Hensley ML; Hirst CM; Ezeoke MO; Ahn L; Qin LX; Antonescu CR; Lefkowitz RA; Maki RG; Schwartz GK; Tap WD
Oncologist; 2019 Jun; 24(6):857-863. PubMed ID: 30126857
[TBL] [Abstract][Full Text] [Related]
10. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.
Ma J; Waxman DJ
Mol Cancer Ther; 2008 Dec; 7(12):3670-84. PubMed ID: 19074844
[TBL] [Abstract][Full Text] [Related]
11. Treating soft tissue sarcomas with adjuvant chemotherapy.
Patrikidou A; Domont J; Cioffi A; Le Cesne A
Curr Treat Options Oncol; 2011 Mar; 12(1):21-31. PubMed ID: 21384115
[TBL] [Abstract][Full Text] [Related]
12. Managing sarcoma: where have we come from and where are we going?
Bleloch JS; Ballim RD; Kimani S; Parkes J; Panieri E; Willmer T; Prince S
Ther Adv Med Oncol; 2017 Oct; 9(10):637-659. PubMed ID: 28974986
[TBL] [Abstract][Full Text] [Related]
13. A precision medicine approach in sarcoma: identification of patients who may benefit from early use of pazopanib.
Alavi SN; Florou V; Tinoco G; Trent JC; Wilky BA
Discov Med; 2018 Mar; 25(137):131-144. PubMed ID: 29641974
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic applications of histone deacetylase inhibitors in sarcoma.
Tang F; Choy E; Tu C; Hornicek F; Duan Z
Cancer Treat Rev; 2017 Sep; 59():33-45. PubMed ID: 28732326
[TBL] [Abstract][Full Text] [Related]
15. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
Kopp HG; Patel S; Brücher B; Hartmann JT
Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
[TBL] [Abstract][Full Text] [Related]
16. Novel agents in development for pediatric sarcomas.
Hughes DP
Curr Opin Oncol; 2009 Jul; 21(4):332-7. PubMed ID: 19444103
[TBL] [Abstract][Full Text] [Related]
17. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
Qiang H; Chang Q; Xu J; Qian J; Zhang Y; Lei Y; Han B; Chu T
J Cancer Res Clin Oncol; 2020 Mar; 146(3):631-645. PubMed ID: 32065262
[TBL] [Abstract][Full Text] [Related]
18. Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs.
Kerbel RS
Cancer Res Treat; 2007 Dec; 39(4):150-9. PubMed ID: 19746237
[TBL] [Abstract][Full Text] [Related]
19. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.
Ryan CW; Desai J
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714556
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas.
Lanzi C; Cassinelli G
Biochem Pharmacol; 2022 Apr; 198():114944. PubMed ID: 35152144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]